Journal of Immunology Research

Journal of Immunology Research / 2016 / Article

Review Article | Open Access

Volume 2016 |Article ID 7346294 |

Moataz Alhaj, "Safety and Efficacy Profile of Commercial Veterinary Vaccines against Rift Valley Fever: A Review Study", Journal of Immunology Research, vol. 2016, Article ID 7346294, 7 pages, 2016.

Safety and Efficacy Profile of Commercial Veterinary Vaccines against Rift Valley Fever: A Review Study

Academic Editor: Leticia Moreno-Fierros
Received03 Mar 2016
Revised13 May 2016
Accepted06 Jun 2016
Published04 Sep 2016


Rift Valley Fever (RVF) is an infectious illness with serious clinical manifestations and health consequences in humans as well as a wide range of domestic ruminants. This review provides significant information about the prevention options of RVF along with the safety-efficacy profile of commercial vaccines and some of RVF vaccination strategies. Information presented in this paper was obtained through a systematic investigation of published data about RVF vaccines. Like other viral diseases, the prevention of RVF relies heavily on immunization of susceptible herds with safe and cost-effective vaccine that is able to confer long-term protective immunity. Several strains of RVF vaccines have been developed and are available in commercial production including Formalin-Inactivated vaccine, live attenuated Smithburn vaccine, and the most recent Clone13. Although Formalin-Inactivated vaccine and live attenuated Smithburn vaccine are immunogenic and widely used in prevention programs, they proved to be accompanied by significant concerns. Despite Clone13 vaccine being suggested as safe in pregnant ewes and as highly immunogenic along with its potential for differentiating infected from vaccinated animals (DIVA), a recent study raised concerns about the safety of the vaccine during the first trimester of gestation. Accordingly, RVF vaccines that are currently available in the market to a significant extent do not fulfill the requirements of safety, potency, and DIVA. These adverse effects stressed the need for developing new vaccines with an excellent safety profile to bridge the gap in safety and immunity. Bringing RVF vaccine candidates to local markets besides the absence of validated serological test for DIVA remain the major challenges of RVF control.

1. Introduction

Rift Valley Fever (RVF) is a life-threatening disease of domestic ruminants and humans, included in OIE list as a notifiable and transmissible disease of serious socioeconomic impacts and public health concerns [1]. The causative agent is Rift Valley Fever virus (RVFV) that belongs to the family Bunyavirridae, genus Phlebovirus [2]. It was first reported among livestock in Kenya in 1931; since then it has been reported as occurring in most African countries [3]. The first appearance of RVF virus in new geographical areas outside Africa was reported in Jazan region, southwest Saudi Arabia, in 2000, with 886 confirmed cases involving 124 deaths in humans [4]. The socioeconomic impact of the RVF epidemics has been higher especially to populations that were totally dependent on livestock as source of income. Studies quantifying the socioeconomic impact of RVF outbreaks are lacking.

In Kenya, during 2006/2007 outbreak, the total economic losses from livestock mortality and potential milk production were calculated at over US$9.3 million and US$77,000, respectively. The negative impacts not only affect livestock producers, but also extend to various stakeholders in the marketing chain including livestock traders due to unsold animals during quarantine, slaughterhouses casual laborers, and butchers who were affected by imposition of slaughter bans during outbreaks [5].

As there is no specific treatment for RVF, vaccination of susceptible animals in endemic and high risk areas with safe and cost-effective vaccine during nonepidemic periods remains the only effective method to build sufficient immunity that is able to prevent virus amplification in livestock, break the cycle of transmission, and eliminate the main source of human infection [6]. Although several adverse effects have been associated with vaccination including injection site reactions, systemic and allergic reactions, residual pathogenicity, and genetic recombination [7], the numerous advantages and the benefits derived have promoted the use of vaccines rather than chemotherapy. Apart from the fact that vaccination is the only available method to prevent viral infections in the absence of broad spectrum antiviral, they are mostly environmentally friendly and contribute indirectly to preventing drug resistance and pharmaceutical residues in food [8]. Furthermore, they have significant impacts not only on reducing losses or improving health and production, but also on human health through increasing safe food supplies and preventing zoonotic diseases [9].

A successful vaccination program depends on a proper selection of vaccine, as well as careful handling practices (in accordance with manufacturer’s instruction). Vaccine type and timing should be done according to the epidemiological aspect of targeted disease. Generally, live attenuated vaccines are more preferable to inactivated ones, since only a single dose is required to provide a long-term immunity. The live attenuated vaccines are recommended in endemic zones and considered the primary available option for controlling the disease in high risk areas during interepizootic period or at an outbreak early warning phase, while inactivated vaccines are advisable in free low risk zones and free high risk areas [10]. However, during an outbreak time of RVF, vector control, public education, quarantine, and slaughter ban probably are the most effective measures against the disease.

Obviously, the commercial production of RVF vaccines tends to be the biggest challenge, as the cost of sustained vaccination campaigns against RVF is beyond the capacity of most countries suffering regular outbreaks. Additionally, outbreaks of RVF usually occurred at irregular intervals and most commonly following exceptionally heavy rains. These events have led to refusing the annual vaccination during long interepizootic periods which in turn both decreases the demand for vaccines and prevents the manufacturers from maintaining strategic stocks due to limited shelf-life.

It could be argued that reliable information about vaccination in endemic zones is scarce. With the exception of Saudi Arabia, South Africa, and Egypt, all affected countries had not practiced routine vaccination (Table 1). In Egypt control of RVF was based on alternation between live and inactivated vaccines concurrent with periodical vector control. Live vaccine has been used at intermittent periods, before, during, or after outbreaks, in unidentified manner which might be a significant factor in disease persistence and maintaining endemicity of RVF in Egypt [14]. In Jazan region, southwest of Saudi Arabia, has had the hardest hit by the disease in 2000. 65.6% of animal cases occurred in Jazan, 26.9% in Asir, and 7.5% in AlQuenfeda. The infection rate was 23%, 8.7%, and 2% in Jazan, Asir, and AlQuenfeda, respectively [15]. Various control measures since then have been in place including sustaining vaccination campaigns, vector control, and surveillance system. Amazingly, the inactivated vaccine was used during the first three weeks of the outbreak despite the risk of RVFV transmission within and between herds through the reuse of needles during vaccination campaign. The inactivated vaccine subsequently was replaced with live attenuated vaccine (Smithburn strain) which has been used as the gold standard vaccine for several years and seems to play a significant role in control, as long as no clinical disease in humans and animals has been reported yet [16].

CountryType of vaccineVaccine scheduleHistorical outbreaks

Saudi ArabiaLive attenuated (Smithburn strain)Annual vaccination2000
South AfricaLive attenuated (Clone13)Annual vaccination (high risk zones)1950, 1974, 1981, 1996, 1999, 2010
EgyptInactivated vaccineBiannual vaccination1977, 1993, 1996, 2003
Kenya and TanzaniaLive attenuated (Smithburn strain)At outbreak warning1931, 1936, 1968, 1978, 1997, 1951, 2006

Currently, two main types of vaccines with different development techniques are available for immunization against RVF, including live attenuated vaccines and inactivated vaccines [17]. Attenuation of live vaccines was accomplished by in vitro passage through a series of cell cultures so as to produce a version of a virus attenuated to such a level unable to cause disease in animals, together with inducing a rapid onset of long lasting immune response similar to that of natural infection. Inactivation was obtained by growing the virus in culture media before treatment with heat or chemicals such as Formalin to destroy the ability of viruses to replicate [18]. Although inactivated vaccines are biologically safe, are more stable, and have no residual viruses or risk of reversion as attenuated vaccines [19], they are still known to be less protective and to need high antigenic mass and strong adjuvant to stimulate the immune system. Moreover, they continued to be associated with slow onset of immunity, local reactogenicity and residue, risk of incomplete inactivation, and hazards to personnel, as well as not being very efficient without multiple injections [20].

To date, there is no licensed vaccines against RVF available to immunize humans, while various strains for livestock are now licensed and commercially produced including Smithburn vaccine, Formalin-Inactivated vaccine, and Clone13. These vaccines are produced by three different laboratories: Onderstepoort Biological Products limited (OBP) in South Africa, Kenya Veterinary Vaccine Producing Institute (KEVEVAPI), and Egypt’s Veterinary Serum and Vaccine Research Institute (EVSVRI) (Table 2).

Commercial vaccine nameVaccine typeFormCompanyAdjuvantPackingInstructed doseUse in pregnant animals

Rift Valley Fever (inactivated)InactivatedLiquidOnderstepoort Biological ProductsAluminum hydroxideAvailable in bottles of 100 mLSheep and goats 1 mL s/c
Cattle 2 mL s/c
Rift Valley Fever (live)Live attenuatedFreeze-driedOnderstepoort Biological ProductsNoAvailable in bottles of 100 dosesCattle, sheep, and goats 1 mL s/c No
RVF Clone13Live attenuatedFreeze-driedOnderstepoort Biological ProductsNoAvailable in bottles of 100 dosesCattle, sheep, and goats 1 mL s/cYes
Rift Valley inactivated vaccineInactivated (Zagazig H501 strain)LiquidVeterinary Serum and Vaccine Research InstituteAluminum hydroxideAvailable in bottles of 100 dosesSheep and goats 1 mL s/c
Cattle 2 mL s/c
RIFTVAX TMLive attenuated Smithburn strainFreeze-driedKenya Veterinary Vaccine Producing InstituteNoAvailable in bottles of 100 dosesSheep and goats 1 mL s/c
Cattle 2 mL s/c

Aims of the Study. This paper specifically aims to(1)summarize commercially available RVF vaccines for veterinary use in Africa and Arabian peninsula,(2)highlight the safety-efficacy profile and drawbacks of these vaccines according to previous safety-efficacy trails.

2. Method of Data Collection

A systematic review was conducted by searching Google Scholar ( and the National Library of Medicine’s Medline database through PubMed ( up to March 15, 2016. The search terms “RVF” and “vaccine” were combined using the operators “AND” and “OR” to identify the original research articles describing the safety and efficacy profile of commercial veterinary vaccines against RVF. A total of 2619 articles were identified by searching Google Scholar and PubMed (2510, 109), respectively. The identified studies were screened on the basis of original research and its relevance to the aim of this review; in addition the full article should be published in English-language. Studies that did not meet inclusion criteria were excluded.

Of 2619 screened reports, 31 articles were finally selected on the basis of inclusion criteria to describe Smithburn vaccine (12 articles), inactivated vaccine (9 articles), and Clone13 (10 articles). Additional studies were obtained through citation tracking of review and original articles.

2.1. Smithburn Vaccine

Smithburn Vaccine Strain was derived from the virulent Entebbe strain, isolated from mosquitoes in Uganda and developed by serial passages in mouse brains to be able to induce immunity in ewes and their offspring after subcutaneous inoculation [21], currently produced in OBP and KEVEVAPI in freeze-dried form. The recommended dose is 1 mL of the reconstituted vaccine administered via subcutaneous route for the immunization of sheep and goats for OBP vaccine whereas cattle received 2 mL of RIFTVAX TM vaccine compared with 1 mL of Rift Valley Fever (Live) produced at OBP. According to manufacturer’s instructions, the vaccine can cause abortion or fetal malformation in a small percentage of animals, particularly sheep, as well as a slight febrile reaction that may occur on the second to fourth day following inoculation. Accordingly, the use should be restricted to nonpregnant animals above six months of age before or at the mating season so as to ensure maternal antibodies and to avoid abortion as well [22]. Despite these adverse outcomes, it has been widely used for many years as the major prevention measure as a cost-effective vaccine in most endemic zones, since the first introduction of the virus [23]. Likewise, in Jazan region, Saudi Arabia, it has been used as the gold standard vaccine for several years as a prevention measure, since 2000 outbreak. It has also been proved through serological surveys to be effective and highly beneficial in controlling infections, as no notable clinical signs in animals have been reported yet [24]. Published efficacy studies conducted in the same region in sheep and goats reported that the vaccine was highly immunogenic and able to induce long lasting antibodies, irrespective of variations among vaccine batches. The level of herd immunity induced by Smithburn Strain Vaccine significantly declined with elapse of years. The percentage of IgG positive animals declined from 95% to 66.7% after one year, and it would decline to zero after six years and eleven months [25]. This decline could be as the consequence of low sensitivity of ELISA test over time. The IgG sandwich ELISA was more sensitive and highly accurate in yearly diagnosis of infection or vaccination with RVF [26]. On the contrary, some safety and potency concerns associated with Smithburn vaccine. The vaccine neither was able to produce proper protective antibodies in all animal species particularly cows, nor was safe in immunocompromised animals and pregnant ones during gestation period leading to high rate of abortion [27]. Larger efficacy and safety study conducted to investigate antibody response to Smithburn vaccine in cattle reported that twenty-eight cows out of 120 pregnant cows and buffalos aborted within three days after vaccination. Moreover, the isolation of the virus from aborted fetus has proved in utero transmission of the vaccine virus [27]. Furthermore, the vaccine virus not only caused abortion and death of fetus at parturition, but also caused harmful changes in internal organs and propagated inside hepatic cells in a manner similar to natural infection [28].

2.2. Formalin-Inactivated Vaccine

The lyophilized vaccine containing 2% Human Serum Albumin was first prepared in African green Monkeys Kidney cell and proved to be safe, immunogenic, and highly resistant to thermal deterioration [29]. Commercially produced from OBP and EVSVRI, the virus strain was adapted for growth in baby hamster Kidney (BHK-21) cell, with aluminum hydroxide gel adjuvant for immunization of cattle, sheep, and goats, irrespective of the age and stage of pregnancy [12]. A safe version of inactivated vaccines with minor side effects named TSI-GSD 200 was developed in USA by using a new master seed of the Entebbe strain. The vaccine is neither licensed for use in human nor commercially available but has been used to protect personnel who either work in laboratories with RVFV or would be exposed to RVF infection, after receiving three doses on days 0, 7, and 28, to provide good long immunity with neutralizing antibody titers (1 : 140) [30]. The safety and efficacy profile of inactivated vaccines have been further investigated in several trials. The immunization of susceptible cattle, sheep, and goats with inactivated vaccine would induce higher neutralizing antibodies persisting for 9 month in cattle with evidence of protections against RVFV in pregnant ewes [31]. A comparative study conducted to assess the response in cattle to live and inactivated RVF vaccines revealed that a booster dose of inactivated vaccine after 3 months of the first vaccination was safe and able to evoke a good response sufficient to protect cattle against RVF for at least 1 year [32]. Further studies were conducted to evaluate the inactivated OBP vaccine as it is extremely difficult to maintain low temperatures during vaccine transportation. The vaccine was stored in different temperatures (4°C, 25°C) with alternation between 4°C and 25°C for a week. It was suggested that the vaccine was stable, well tolerated with mild or limited adverse reactions, and not adversely affected by variation in temperature during transportation and that induced long-term neutralizing antibodies may persist for 21 months after booster dose at any age and any stage of pregnancy [33, 34].

2.3. Clone13 Vaccine

Although, Formalin-Inactivated vaccine and live attenuated Smithburn vaccine are widely used in control, both of them were accompanied by significant concerns. The first one requires multiple doses for protection, and the second has a risk of causing abortion and fetal malformation in pregnant animals [35]. Drawbacks of these vaccines stressed the need for alternative vaccines in terms of safety and efficiency. Consequently, a massive progress and several initiatives have been done for the evolution of modern vaccines. Recent studies have shown that RVF virus vaccines containing deletions of the NSs and NSm genes are highly attenuated, confer protective immunity with no detectable viremia, and could be useful in control of RVF virus in endemic regions, as well as allowing for DIVA [36]. The commercial OBP vaccine named (RVF Clone13) has recently been registered, marketed in a form of freeze-dried live attenuated virus (Clone13 strain), and extensively used in South Africa [37]. Clone13 is a naturally attenuated isolate of RVF virus with a large deletion in the S segment. It was cloned by plaque purification of nonfatal human case isolate (74HB59 strain), obtained during 1974 RVF outbreak in Central African Republic, and proved to be highly immunogenic leading to long-term immunity as well [38]. Published efficacy and safety studies of Clone13 vaccine have shown that the vaccine protects animals properly without inducing undesirable clinical signs, such as abortion in pregnant ewes, pyrexia, or fetal malformation in their offspring [39]. Recent efficacy and safety studies conducted in sheep and goats in Senegal stipulated that the vaccine was safe at stages of pregnancy and did not induce adverse effects. Additionally, more than 70% of the vaccinated sheep and goats showed that long-term seroconversion persisted for 1 year after vaccination [40]. However, some safety studies raised concerns about the possibility of genetic reassortant between S segment in Clone13 vaccine and virulent strains in field [41]. Furthermore, in a more recent study, it was reported that the vaccine virus is able to cross the ovine placental barrier and spread to the fetus resulting in malformations and stillbirths [42]. Remarkably, the vaccine has the potential to be used as DIVA vaccine for RVF, but the accompanying diagnostic tests are not yet commercially available [43].

Although the currently available commercial vaccines have made great contributions to RVF control over the past 80 years, they are associated with some safety and efficacy concerns, including, but not limited to, risk of abortion, pyrexia, fetal malformation, teratogenic effects, viraemia, risk of reassortment, short shelf-life, revaccination, and risk of incomplete inactivation in killed vaccines (Table 3). The gap in the safety and immunity explains the need for new promising candidates currently under development, such as subunit vaccines, virus vector, and replicons [44, 45]. The most prominent among these candidates is a recombinant Capripoxvirus (CPV) vaccine which was developed to protect against RVFV as well as against sheep poxvirus infection. Promising results have been reported in Preclinical Stage trials including safety in pregnant ewes and offspring, stability of the vaccine, and its potential for DIVA [46].

Commercial vaccine nameSafety profilePersistence duration of antibodiesCost

Rift Valley Fever (live)Cause abortion in pregnant ewes
Cause teratogenic effects
Cause significant level of viraemia
Risk of reversion to virulence
Long-term immunity
Single dose
Low price

RVF Clone13Safe in pregnancy
Very low viraemia
Risk of genetic reassortment
Restricted to endemic zones
Short shelf-life
Single dose
Lon-term immunity
Low price

Rift Valley Fever (inactivated)Safe in pregnancy
Can be used during outbreaks
Can be used in low risk zones
Booster dose is required
Annual revaccination
Not practical in routine vaccination
High cost

3. Conclusion

To sum up, the study has come out with some important results which can be summarized as follows.

First, commercial vaccines currently available in the market are lacking safety and DIVA.

Second, live attenuated Smithburn was reported to cause abortion and fetal malformation in pregnant ewes.

Third, Formalin-Inactivated vaccine requires multiple doses or annual revaccination to provide protection which renders the vaccine not recommended in endemic zones.

Fourth, the safety of Clone13 during the first trimester of gestation remains controversial as it has been reported that the vaccine causes malformations and stillbirths.

Fifth, drawbacks of currently available vaccines stress the need for developing and bringing vaccine candidates to markets in near future to fill the gap in safety and immunogenicity.

Finally, validated serological test for DIVA should be considered in future researches.

Competing Interests

The author declares that they have no competing interests.


  1. World Organization for Animal Health, “OIE-Listed diseases, infections and infestations in force in 2015,” View at: Google Scholar
  2. World Health Organization (WHO), Rift Valley Fever. Fact sheet, 2010,
  3. R. Daubney, J. R. Hudson, and P. C. Garnham, “Enzootic hepatitis or Rift Valley Fever. An undescribed virus disease of sheep cattle and man from East Africa,” The Journal of Pathology and Bacteriology, vol. 34, no. 4, pp. 545–579, 1931. View at: Publisher Site | Google Scholar
  4. H. H. Balkhy and Z. A. Memish, “Rift Valley fever: an uninvited zoonosis in the Arabian peninsula,” International Journal of Antimicrobial Agents, vol. 21, no. 2, pp. 153–157, 2003. View at: Publisher Site | Google Scholar
  5. K. M. Rich and F. Wanyoike, “An assessment of the regional and national socio-economic impacts of the 2007 Rift Valley fever outbreak in Kenya,” The American Journal of Tropical Medicine and Hygiene, vol. 83, no. 2, pp. 52–57, 2010. View at: Publisher Site | Google Scholar
  6. B. H. Bird and S. T. Nichol, “Breaking the chain: Rift Valley fever virus control via livestock vaccination,” Current Opinion in Virology, vol. 2, no. 3, pp. 315–323, 2012. View at: Publisher Site | Google Scholar
  7. S. Martinod, “Risk assessment related to veterinary biologicals: side-effects in target animals,” Revue Scientifique et Technique, vol. 14, no. 4, pp. 979–989, 1995. View at: Google Scholar
  8. P. P. Pastoret and P. Jones, “Veterinary vaccines for animal and public health,” Developments in Biologicals, vol. 119, pp. 15–29, 2004. View at: Google Scholar
  9. E. N. T. Meeusen, J. Walker, A. Peters, P.-P. Pastoret, and G. Jungersen, “Current status of veterinary vaccines,” Clinical Microbiology Reviews, vol. 20, no. 3, pp. 489–510, 2007. View at: Publisher Site | Google Scholar
  10. World Organization for Animal Health, Rift Valley Fever, OIE Terrestrial Manual 2014, chapter 2.1.14:11, World Organization for Animal Health, Paris, France, 2014,
  13. T. Ikegami and S. Makino, “Rift Valley fever vaccines,” Vaccine, vol. 27, no. 4, pp. D69–D72, 2009. View at: Publisher Site | Google Scholar
  14. S. A. Kamal, “Observations on Rift Valley fever virus and vaccines in Egypt,” Virology Journal, vol. 8, article 532, 2011. View at: Google Scholar
  15. A. A. Alfadil, S. M. Musa, M. Alkhamees, D. Al Mujalli, and K. Al Ahmed, “Epidemiologic study on Rift Valley Fever—in south-west Kingdom of Saudi Arabia,” Journal of Science and Technology, vol. 5, no. 1, pp. 110–119, 2004. View at: Google Scholar
  16. A. M. Abdelhamid and S. M. MSami, “Serological survey of rift valley fever in jazan region, Saudi Arabia,” Journal of Science and Technology, vol. 7, no. 1, pp. 5–13, 2006. View at: Google Scholar
  17. T. Ikegami and S. Makino, “Rift Valley fever vaccines,” Vaccine, vol. 27, supplement 4, pp. D69–D72, 2009. View at: Publisher Site | Google Scholar
  18. Centers for Disease Control and Prevention (CDC), Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook, 12th edition, 2012.
  19. S. J. Barteling and R. Woortmeyer, “Formaldehyde inactivation of foot-and-mouth disease virus. Conditions for the preparation of safe vaccine,” Archives of Virology, vol. 80, no. 2-3, pp. 103–117, 1984. View at: Publisher Site | Google Scholar
  20. J. M. Minke, J.-C. Audonnet, and L. Fischer, “Equine viral vaccines: the past, present and future,” Veterinary Research, vol. 35, no. 4, pp. 425–443, 2004. View at: Publisher Site | Google Scholar
  21. K. C. Smithburn, “Rift Valley Fever; the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine,” The British Journal of Experimental Pathology, vol. 30, no. 1, pp. 1–16, 1949. View at: Google Scholar
  23. F. G. Davies, “The historical and recent impact of Rift Valley fever in Africa,” The American Journal of Tropical Medicine and Hygiene, vol. 83, no. 2, pp. 73–74, 2010. View at: Publisher Site | Google Scholar
  24. A. M. Abdelhamid and S. M. Sami, “Serological survey of Rift Valley Fever in Jazan Region, Saudi Arabia,” Sudan Journal of Science and Technology, vol. 7, no. 1, pp. 5–13, 2006. View at: Google Scholar
  25. A. Ahmed Mohamed Elfadil and E. S. Shaheen, “Persistence duration of immunoglobulin G antibodies to rift valley fever virus in sheep and goats sera after vaccination,” Sudan Journal of Science and Technology, vol. 8, no. 1, 2007, View at: Google Scholar
  26. J. T. Paweska, F. J. Burt, F. Anthony et al., “IgG-sandwich and IgM-capture enzyme-linked immunosorbent assay for the detection of antibody to Rift Valley fever virus in domestic ruminants,” Journal of Virological Methods, vol. 113, no. 2, pp. 103–112, 2003. View at: Publisher Site | Google Scholar
  27. B. Botros, A. Omar, K. Elian et al., “Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine,” Journal of Medical Virology, vol. 78, no. 6, pp. 787–791, 2006. View at: Publisher Site | Google Scholar
  28. S. A. Kamal, “Pathological studies on postvaccinal reactions of Rift Valley fever in goats,” Virology Journal, vol. 6, article 94, 2009. View at: Publisher Site | Google Scholar
  29. L. Binn and V. Harrison, “Studies on the immunogenicity of lyophilized formalin-inactivated vaccine,” Journal of Immuniology, vol. 93, no. 2, pp. 293–299, 1964. View at: Google Scholar
  30. P. R. Pittman, C. T. Liu, T. L. Cannon et al., “Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience,” Vaccine, vol. 18, no. 1-2, pp. 181–189, 1999. View at: Publisher Site | Google Scholar
  31. B. J. Barnard and M. J. Botha, “An inactivated rift valley fever vaccine,” Journal of the South African Veterinary Association, vol. 48, no. 1, pp. 45–48, 1977. View at: Google Scholar
  32. B. J. H. Barnard, “Rift Valley fever vaccine—antibody and immune response in cattle to a live and an inactivated vaccine,” Journal of the South African Veterinary Association, vol. 50, no. 3, pp. 155–157, 1979. View at: Google Scholar
  33. N. Lagerqvist, B. Moiane, G. Bucht et al., “Stability of a formalin-inactivated Rift Valley fever vaccine: evaluation of a vaccination campaign for cattle in Mozambique,” Vaccine, vol. 30, no. 46, pp. 6534–6540, 2012. View at: Publisher Site | Google Scholar
  34. J. M. Rusnak, P. Gibbs, E. Boudreau, D. P. Clizbe, and P. Pittman, “Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study,” Vaccine, vol. 29, no. 17, pp. 3222–3229, 2011. View at: Publisher Site | Google Scholar
  35. S. V. Indran and T. Ikegami, “Novel approaches to develop RVF vaccines,” Frontiers in Cellular and Infection Microbiology, vol. 2, article 131, 2012. View at: Publisher Site | Google Scholar
  36. B. H. Bird, C. G. Albariño, A. L. Hartman, B. R. Erickson, T. G. Ksiazek, and S. T. Nichol, “Rift Valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals,” Journal of Virology, vol. 82, no. 6, pp. 2681–2691, 2008. View at: Publisher Site | Google Scholar
  37. J. Kortekaas, J. Zingeser, P. de Leeuw, S. de La Rocque, H. Unger, and R. J. M. Moormann, “Rift valley fever vaccine development, progress and constraints,” Emerging Infectious Diseases, vol. 17, no. 9, article e1, 2011. View at: Google Scholar
  38. R. Muller, J.-F. Saluzzo, N. Lopez et al., “Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment,” The American Journal of Tropical Medicine and Hygiene, vol. 53, no. 4, pp. 405–411, 1995. View at: Google Scholar
  39. B. Hunter, I. Louw, A. Lubisi, B. Hunter, B. F. Von teichman, and M. Bouloy, “Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep,” Vaccine, vol. 28, no. 29, pp. 4581–4587, 2010. View at: Publisher Site | Google Scholar
  40. M. M. Lo, V. Mbao, P. Sierra et al., “Safety and immunogenicity of onderstepoort biological products’ rift valley fever clone 13 vaccine in sheep and goats under field conditions in senegal,” Onderstepoort Journal of Veterinary Research, vol. 82, no. 1, 2015. View at: Publisher Site | Google Scholar
  41. M. Bouloy, C. Janzen, P. Vialat et al., “Genetic evidence for an interferon-antagonistic function of Rift Valley fever virus nonstructural protein NSs,” Journal of Virology, vol. 75, no. 3, pp. 1371–1377, 2001. View at: Publisher Site | Google Scholar
  42. B. Makoschey, E. van Kilsdonk, W. R. Hubers et al., “Rift valley fever vaccine virus clone 13 is able to cross the ovine placental barrier associated with foetal infections, malformations, and stillbirths,” PLOS Neglected Tropical Diseases, vol. 10, no. 3, article e0004550, 2016. View at: Publisher Site | Google Scholar
  43. W. C. Wilson, M. Romito, D. C. Jasperson et al., “Development of a Rift Valley fever real-time RT-PCR assay that can detect all three genome segments,” Journal of Virological Methods, vol. 193, no. 2, pp. 426–431, 2013. View at: Publisher Site | Google Scholar
  44. S. V. Indran and T. Ikegami, “Novel approaches to develop Rift Valley fever vaccines,” Frontiers in Cellular and Infection Microbiology, vol. 2, article 131, 2012. View at: Publisher Site | Google Scholar
  45. G. M. Warimwe, J. Gesharisha, B. V. Carr et al., “Chimpanzee adenovirus vaccine provides multispecies protection against rift valley fever,” Scientific Reports, vol. 6, Article ID 20617, 2016. View at: Publisher Site | Google Scholar
  46. R. K. Soi, F. R. Rurangirwa, T. C. McGuire, P. M. Rwambo, J. C. DeMartini, and T. B. Crawford, “Protection of sheep against Rift Valley fever virus and sheep poxvirus with a recombinant capripoxvirus vaccine,” Clinical and Vaccine Immunology, vol. 17, no. 12, pp. 1842–1849, 2010. View at: Publisher Site | Google Scholar

Copyright © 2016 Moataz Alhaj. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.